EN
TR
Evaluation of Nociceptive Flexor Reflex Response in Patients with Painful Idiopathic Parkinson's Disease
Abstract
Aim: We aimed to investigate the utility of trigeminocervical reflex (TCR) and nociceptive flexion reflex (NFR) as objective measures for assessing pain—a common NMS—in patients with PD, targeting both the upper and lower body regions.
Methods: All subjects were further classified into four groups: Group-I: Healthy individuals without PD or pain, Group-II: Individuals without PD but reporting non-specific musculoskeletal pain, Group-III: PD patients without pain, Group-IV: PD patients with pain as a NMS. The clinical assessment of PD was conducted using the Hoehn and Yahr Staging Scale (HYS) and the Unified Parkinson's Disease Rating Scale (UPDR). We divided the human body into upper and lower regions—utilizing the TCR for upper body pain and the NFR for pain around the lumbar and pelvic areas.
Results: The Group-IV had a longer mean disease duration than those in Group-III (8.0±6.6 vs 3.0±3.5 and p=0.121). The mean UPDRS score significantly higher in Group-IV compared to Group-III (42.5±13 vs 27.4±15.3 and p=0.022). The mean VAS score was 7.0±0.7 in Group-II and 6.3±1.3 in Group-IV, with no significant differences in pain localization or VAS scores between the two-groups.
Conclusion: Electrophysiological reflex assessments do not appear to be sufficiently reliable in evaluating pain perception in these patients.
Keywords
Destekleyen Kurum
Yok
Etik Beyan
Çalışma için İstanbul Üniversitesi Etik Kurulu’ndan onay alındı.
Teşekkür
Yok
Kaynakça
- 1.de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006 Jun;5(6):525-35. [Crossref]
- 2.Poewe W. Treatments for Parkinson disease--past achievements and current clinical needs. Neurology. 2009 Feb 17;72(7 Suppl):S65-73. [Crossref]
- 3.GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017 Nov;16(11):877-897. [Crossref]
- 4.Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):368-76. [Crossref]
- 5.Chaudhuri KR, Healy DG, Schapira AH; National Institute for Clinical Excellence. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006 Mar;5(3):235-45. [Crossref]
- 6.Stoyanova-Piroth G, Milanov I, Stambolieva K. Association between pain threshold and manifested pain assessed using a PD-specific pain scale in Parkinson's disease. Front Neurol. 2024 Jul 25;15:1420696. [Crossref]
- 7.Grigoriou S, Martínez-Martín P, Ray Chaudhuri K, Rukavina K, Leta V, Hausbrand D, Falkenburger B, Odin P, Reichmann H. Effects of safinamide on pain in patients with fluctuating Parkinson's disease. Brain Behav. 2021 Oct;11(10):e2336. [Crossref]
- 8.Tinazzi M, Recchia S, Simonetto S, Tamburin S, Defazio G, Fiaschi A, Moretto G, Valeriani M. Muscular pain in Parkinson's disease and nociceptive processing assessed with CO2 laser-evoked potentials. Mov Disord. 2010 Jan 30;25(2):213-20. [Crossref]
Ayrıntılar
Birincil Dil
İngilizce
Konular
Klinik Tıp Bilimleri (Diğer)
Bölüm
Araştırma Makalesi
Yayımlanma Tarihi
31 Aralık 2025
Gönderilme Tarihi
23 Kasım 2025
Kabul Tarihi
21 Aralık 2025
Yayımlandığı Sayı
Yıl 2025 Cilt: 8 Sayı: 4